Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis.

ABSTRACT:

Background

Molnupiravir is an essential oral antiviral agent against coronavirus disease 2019 (COVID-19); however, its real-world effectiveness has not been evaluated in patients undergoing haemodialysis (HD).

Methods

This multi-centre retrospective study, involving 225 patients undergoing HD with initially mild or asymptomatic COVID-19, was conducted to compare the risks of 30-day COVID-19-related acute care visits between patients receiving and not receiving molnupiravir. Patients who received molnupiravir were stratified by rapid antigen detection (RAD) test results on day 7 after disease onset to assess whether rapid molnupiravir introduction accelerated viral clearance.

Results

Thirty-day COVID-19-related acute care visits were reported in 9.41% and 21.74% of the

SUBMITTER: Chang YC 

PROVIDER: S-EPMC10148756 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature